<DOC>
	<DOCNO>NCT01558869</DOCNO>
	<brief_summary>This open-label , single centre , single-arm phase II study aim assess efficacy tolerability triplet combination capecitabine , oxaliplatin irinotecan ( Xeloxiri regimen ) treat patient advance unresectable pancreatic carcinoma . Clinical data patient diagnose pancreatic adenocarcinoma collect analyzed study . The patient ' data collect maintained Division Medical Oncology University Department Medicine , Queen Mary Hospital , Hong Kong .</brief_summary>
	<brief_title>Xeloxiri First-line Treatment Patients With Advanced Unresectable Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Adults ≥ 18 year age , male female . Histopathologically cytologically confirm adenocarcinoma pancreas . ECOG performance status 0 2 . Adequate bone marrow reserve . Absolute neutrophil count &gt; 1x10^9/L . Total bilirubin &lt; 3 time upper limit normal range . Life expectancy ≥ 12 week . Signed write informed consent form . Prior malignant disease pancreatic cancer . Patients suitable surgical locoregional therapy . Patients prior anticancer therapy pancreatic cancer . Patients unable swallow oral medication . Any evidence brain metastasis ( unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) . Active clinically serious infection ( &gt; grade 2 NCI / CTC Adverse Event version 3.0 ) . History allergy platinum compound . Patients chronic inflammatory bowel disease and/or bowel obstruction . Patients severe bone marrow failure . Patients undergoing renal dialysis . History HIV infection . Seizure disorder require medication ( steroids antiepileptic ) . Women pregnant breastfeeding , woman childbearing potential unable unwilling practice highly effective mean contraception . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>